BIO-RAD LABORATORIES, INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.58B | $2.57B | $2.67B | $2.80B | $2.92B | $2.55B | $2.31B | $2.29B |
| Cost of Revenue | $1.24B | $1.19B | $1.24B | $1.23B | $1.28B | $1.11B | $1.05B | $1.07B |
| Gross Profit | $1.34B | $1.38B | $1.43B | $1.57B | $1.64B | $1.44B | $1.26B | $1.22B |
| Gross Margin | 51.9% | 53.7% | 53.4% | 55.9% | 56.1% | 56.5% | 54.4% | 53.4% |
| Operating Expenses | ||||||||
| Research & Development | $275.6M | $295.9M | $247.4M | $256.9M | $260.6M | $217.8M | $202.7M | $199.2M |
| SG&A Expense | $844.3M | $814.0M | $841.7M | $827.8M | $877.1M | $798.8M | $824.6M | $834.8M |
| Operating Income | $47.2M | $269.0M | $337.8M | $482.6M | $500.3M | $421.3M | $229.7M | $-103.3M |
| Operating Margin | 1.8% | 10.5% | 12.6% | 17.2% | 17.1% | 16.6% | 9.9% | -4.5% |
| Interest Expense | $49.0M | $48.9M | $49.4M | $38.1M | $1.6M | $21.9M | $23.4M | $24.0M |
| Pretax Income | $995.5M | $-2.34B | $-850.1M | $-4.70B | $5.45B | $4.92B | $2.26B | $512.7M |
| Income Tax Expense | $235.6M | $-498.3M | $-212.8M | $-1.08B | $1.19B | $1.10B | $502.4M | $147.0M |
| Net Income | $759.9M | $-1.84B | $-637.3M | $-3.63B | $4.25B | $3.81B | $1.76B | $365.6M |
| Net Margin | 29.4% | -71.9% | -23.9% | -129.5% | 145.6% | 149.8% | 76.1% | 16.0% |
| EPS (Basic) | $27.87 | $-65.36 | $-21.82 | $-121.79 | $142.61 | $128.13 | $58.93 | $12.25 |
| EPS (Diluted) | $27.85 | $-65.36 | $-21.82 | $-121.79 | $140.83 | $126.47 | $58.27 | $12.10 |
| Shares Outstanding (Basic) | 27.3M | 28.2M | 29.2M | 29.8M | 29.8M | 29.8M | 29.8M | 29.8M |
| Shares Outstanding (Diluted) | 27.3M | 28.2M | 29.2M | 29.8M | 30.2M | 30.2M | 30.2M | 30.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |